USPTO Rules On Stem Cell Patents In Biotech Battle
Palo Alto, Calif.-based StemCells said Friday that the patent office had issued notices of intent to issue ex parte re-examination certifications for U.S. Patent Numbers 6,294,346 and 7,101,709, which relate to the use of human stem cells for screening drugs and for screening biological agents, respectively.
The patents are among six patents StemCells...
Already a subscriber? Click here to login